• Dapps:16.23K
  • Blockchains:78
  • Active users:66.47M
  • 30d volume:$303.26B
  • 30d transactions:$879.24M

SEC Sues Elon Musk for Delay in Twitter Stock Disclosure

user avatar

by Giorgi Kostiuk

a year ago


The Securities and Exchange Commission (SEC) has filed a lawsuit against Elon Musk, alleging that the billionaire delayed disclosing his acquisition of Twitter Inc. shares.

SEC Lawsuit Against Musk

The case, titled *Securities and Exchange Commission v. Musk*, is docketed in the U.S. District Court for the District of Columbia. The complaint alleges that Musk intentionally missed the deadline to disclose his acquisition of more than a 5% stake in Twitter early in 2022.

Allegations of Twitter Stock Manipulation

The SEC claims Musk delayed disclosure to buy Twitter shares at artificially low prices, resulting in an underpayment of at least $150 million. By March 2022, Musk held more than 9% of Twitter's stock. Federal securities law required him to disclose this within 10 days, but his filing was delayed by 11 days.

The SEC’s multi-year campaign of harassment against Mr. Musk culminates in this filing of a single-count, administrative complaint under Section 13(d) for allegedly failing to submit one form—a procedural issue that, even if substantiated, would result in a nominal penalty.Alex Spiro

Penalties and Musk's Political Ties

The SEC seeks court-ordered penalties against Musk, including the repayment of profits deemed to be unjustly acquired. Musk is also facing investor lawsuits accusing him of concealing his Twitter stock acquisition. Additionally, Musk has gained political prominence as a supporter and advisor to Donald Trump.

The SEC's legal actions against Elon Musk add another chapter to his complex relationship with regulatory entities and political figures, raising questions about his business practices and political ties.

0

Rewards

chest
chest
chest
chest

More rewards

Discover enhanced rewards on our social media.

chest

Other news

Converge Bio's AI Platform Aims to Transform Drug Development

chest

Converge Bio is leveraging its newly acquired $25 million funding to enhance its AI platform, which focuses on drastically reducing the time and costs associated with drug development.

user avatarKenji Takahashi

Converge Bio Secures $25 Million Series A Funding to Transform Drug Discovery

chest

Converge Bio, a startup based in Boston and Tel Aviv, has raised $25 million in Series A funding to enhance AI-driven drug discovery.

user avatarMaria Fernandez

Buterin Continues Charity Donations from Token Sales

chest

Vitalik Buterin continues his practice of selling unsolicited tokens and donating the proceeds to charity, emphasizing ethical considerations in cryptocurrency promotions.

user avatarRajesh Kumar

Vitalik Buterin Sells Unsolicited Tokens for 94 ETH

chest

Ethereum cofounder Vitalik Buterin has sold unsolicited tokens from his wallet, converting them into 94 ETH.

user avatarGustavo Mendoza

Grayscale Segments Crypto Market into Five Vertical Categories

chest

Grayscale has categorized its altcoin candidates into five verticals, reflecting a structured approach to the crypto market.

user avatarMiguel Rodriguez

Decline in FLOW Price Amid Controversial Asset Recovery

chest

The price of FLOW has seen a significant decline following the Flow project's controversial asset recovery actions.

user avatarLuis Flores

Important disclaimer: The information presented on the Dapp.Expert portal is intended solely for informational purposes and does not constitute an investment recommendation or a guide to action in the field of cryptocurrencies. The Dapp.Expert team is not responsible for any potential losses or missed profits associated with the use of materials published on the site. Before making investment decisions in cryptocurrencies, we recommend consulting a qualified financial advisor.